Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-001 subretinal gene therapy in RPE65 biallelic mutation–associated retinal degeneration
CTR20222868Phase 2Active
- Sponsor
- Frontera Therapeutics
- Start
- Jan 2023
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of FT-001 in RPE65 deficiency, Leber congenital amaurosis type 2 (LCA2), retinitis pigmentosa (RP), sponsored by Frontera Therapeutics. Started Jan 2023; status: active.
02
Drugs
FT-001
03
Conditions
RPE65 deficiencyLeber congenital amaurosis type 2 (LCA2)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on CTR20222868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222868.